Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT).

F KrackhardtM WaliszewskiJ RischnerC PiotM PansieriF L Ruiz-PovedaM BoxbergerM NoutsiasX F RíosBehrouz Kherad

Published in: Herz (2018)

PF-SES are safe and effective in daily clinical routine with low rates of TLR and MACE in patients with diabetes and stable disease. Our data suggest that extending the duration of DAPT beyond 6 months does not improve MACE or TLR at 9 months in patients with stable CAD (ClinicalTrials.gov Identifier NCT02629575).

Keyphrases

antiplatelet therapy
acute coronary syndrome
percutaneous coronary intervention
toll like receptor
inflammatory response
coronary artery disease
immune response
electronic health record
physical activity
clinical practice
nuclear factor
big data
deep learning